Request Demo

Last update 15 Jun 2026

Albumin-Bound Paclitaxel

Last update 15 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Nab-Paclitaxel, Nab-PTX, Paclitaxel Albumin Nanoparticles

+ [18]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [8]

Active Indication

Advanced breast cancerNeoplasmsMetastatic Pancreatic Cancer+ [41]

Inactive Indication

Adenocarcinoma of large intestineAdenocarcinoma of small intestineAdenosquamous Carcinoma+ [113]

Originator Organization

CSPC Pharmaceutical Group Ltd.

Abraxis BioScience, Inc.

Active Organization

Zhejiang Haichang Bio-Tech Co., Ltd.BeiGene 101 Ltd.Hoffmann-La Roche, Inc.

+ [14]

Inactive Organization

Genentech, Inc.

Novartis Pharmaceuticals Corp.

Novartis AG

+ [12]

License Organization

Zhejiang Haichang Bio-Tech Co., Ltd.

BeOne Medicines Ltd.

Kexing Biopharm Co., Ltd.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (07 Jan 2005),

Metastatic breast cancer

Regulation-

Structure/Sequence

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

2,454

Clinical Trials associated with Albumin-Bound Paclitaxel

NCT06592664

/ WithdrawnPhase 1/2

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

Start Date01 Jan 2030

Sponsor / Collaborator

Lisata Therapeutics, Inc.

NCT07610525

/ Not yet recruitingPhase 2

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Tria

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Start Date05 Nov 2026

Sponsor / Collaborator-

NCT07234877

/ Not yet recruitingPhase 2IIT

A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC

This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally.
Approximately 158 patients will be randomized in a 1:1 ratio. Will be included patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment available and active asymptomatic brain metastasis (newly diagnosed or progressive).
The primary objective is to compare iPFS between the two arms.

Start Date01 Nov 2026

Sponsor / Collaborator

European Organisation for Research & Treatment of Cancer

[+1]

100 Clinical Results associated with Albumin-Bound Paclitaxel

100 Translational Medicine associated with Albumin-Bound Paclitaxel

100 Patents (Medical) associated with Albumin-Bound Paclitaxel

22,548

Literatures (Medical) associated with Albumin-Bound Paclitaxel

31 Dec 2026·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

Author: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·DRUG DELIVERY

The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity

Article

Author: Jiang, Chengwei ; Schätzlein, Andreas G. ; Uchegbu, Ijeoma F. ; Xiong, Guojun

Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (α-helix = 17%) is structurally denatured compared with native HSA (α-helix = 68%), leading to rapid clearance (<1 h) from the circulation and that drug loading is driven by pharmaceutical HSA's amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (ζ = -13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (<0.1 mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (ζ = -27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (<0.01 mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, p < 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles.

1,067

News (Medical) associated with Albumin-Bound Paclitaxel

15 Jun 2026

·www.biospace.com

Immuneering Appoints Andrew Gengos as Chief Financial Officer

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. At Immuneering, Mr. Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities as the company advances atebimetinib, its lead oncology candidate in Phase 3, and a pipeline of other deep cyclic inhibitors. “Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation,” said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. “His experience as a CFO, business development leader, and strategic advisor will be invaluable as we advance our clinical programs and prepare for the next phase of Immuneering's growth. We are delighted to welcome Andrew to our leadership team.” “I am thrilled to join Immuneering at such an exciting time in the company's development,” said Andrew Gengos. “Atebimetinib is now a Phase 3 candidate in first-line pancreatic cancer, supported by recently presented survival and tolerability data that are highly encouraging in a disease where new treatment options are urgently needed. A growing body of data supports the potential of Immuneering’s differentiated deep cyclic inhibitor technology to benefit patients with RAS, RAF, and other MAPK-driven cancers. I believe we are in the early chapters of this compelling story and look forward to working with Immuneering’s leadership team and Board to advance atebimetinib through late-stage development and create value for patients and shareholders alike.” Prior to joining Terns, Mr. Gengos served as Chief Financial Officer and Chief Business Officer of Athira Pharma, Inc. (now LeonaBio, Inc.). Previously, he served as Chief Business Officer of Cyteir Therapeutics, Inc., where he led the finance organization that successfully completed the company's initial public offering. Earlier in his career, he served as Chief Executive Officer of ImmunoCellular Therapeutics, Ltd. and Neuraltus Pharmaceuticals, Inc., providing strategic and financial leadership across oncology and neurodegenerative disease programs. In addition, Mr. Gengos was Vice President of Strategy and Corporate Development at Amgen Inc., where for eight years he helped shape the company's long-term strategic priorities and business development initiatives. He began his career at Morgan Stanley and later joined McKinsey & Company, advancing from Associate to Senior Engagement Manager. Mr. Gengos holds an MBA from the UCLA Anderson School of Management and a BS in Chemical Engineering from the Massachusetts Institute of Technology. About Immuneering Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer; the timing of dosing of the MAPKeeper 301 study and the timing of topline results from the study; the timing of dosing of the Phase 2 combination study of atebimetinib in non-small cell lung cancer, including the timing of preliminary results from the study; timing of IND-enabling studies from the next DCI drug program; the ability of phase 2 results presented at ASCO to translate to success and support evaluation in the Company’s phase 3 study; the ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in activating trial sites or enrolling trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Investor Contact: Courtney Dugan Cdugan@immuneering.com Media Contact: Peg Rusconi peg.rusconi@deerfieldgroup.com

Phase 2Executive ChangePhase 3

11 Jun 2026

·www.prnewswire.com

Airiver Medical Treats First Patient in Pivotal Clinical Study of the Airiver Drug Coated Balloon for Patients with Chronic Rhinosinusitis

The nationwide study will assess the safety and efficacy of the technology that combines standard balloon dilation to open the nasal passageways with drug delivery designed to maintain symptom relief BROOKLYN PARK, Minn., June 11, 2026 /PRNewswire/ -- Airiver Medical, a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions, today announced the successful treatment of the first patient with chronic rhinosinusitis (CRS) in its RESTORE-2 U.S. pivotal clinical trial of the Airiver ESSpand Sinus Drug Coated Balloon (DCB). The first patient was treated by Dr. Andrew Gould, board-certified ENT and director of research at Advanced ENT and Allergy in Louisville, Ky. Dr. Gould has been enrolling patients in clinical trials over the past 25 years. "We're thrilled to have treated the first patient in this important study and very hopeful that this will provide meaningful improvements in outcomes for endoscopic sinus surgery," said Dr. Gould. "If the RESTORE-2 trial is successful, this technology could help patients avoid further surgeries, oral steroids, and expensive biologic therapy – a huge potential win for patients and the healthcare system." The landmark study is enrolling up to 300 patients suffering from CRS with and without nasal polyps and is being conducted across the U.S. to assess the safety and efficacy of the investigational ESSpand DCB as an adjunct to endoscopic sinus surgery (ESS). The ESSpand DCB is designed to maintain symptom relief and prevent scarring and renarrowing of drainage passageways by applying a thin layer of a proprietary paclitaxel drug coating to the targeted tissue contemporaneously with balloon dilation of the restricted sinus drainage passageways. The study is intended to serve as the basis for Airiver Medical's regulatory submission to the FDA and eventual commercialization of the ESSpand DCB in the U.S. "This is an important milestone as we're one step closer to providing patients suffering from CRS and physicians with our novel treatment option that has the potential for long-term relief with fewer treatments, which is a significant gap in current treatment options," said Paul Vajgrt, CEO of Airiver Medical. "We thank Dr. Gould and his team, the patients and health care providers participating in the clinical trial, and our team for their dedication to bringing this therapy to patients who are seeking a long-term option." CRS is defined as long-term (present for a minimum of three months despite intervention) symptomatic inflammation of the nose and paranasal sinuses. CRS is one of the most common chronic medical conditions in the world, with more than 14 million U.S. adults suffering from the condition. Four million of these patients cite challenges finding relief through traditional medical treatments, as medication alone is sometimes not enough, and they may choose to undergo surgery. Despite this initial surgery, symptoms often return and many patients undergo at least one additional surgery. In addition to the RESTORE-2 clinical trial, Airiver Medical is also enrolling patients in the OXYGEN-RCT U.S. pivotal clinical study, assessing the safety and efficacy of the investigational Airiver Pulmonary DCB in patients with central airway stenosis. This trial has currently treated 21 patients and will enroll up to 200. The Airiver DCB is an investigational device. The Airiver DCB has not received marketing authorization from the FDA and is not available for sale in the United States. About Airiver Medical Airiver Medical is a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions. The company aims to improve the current standard of care for central airway stenosis and chronic rhinosinusitis. Airiver Medical's Drug Coated Balloon could offer a new solution for these conditions, potentially creating sustained patency, better outcomes and fewer treatments. For more information, please visit . Media Contact: Shelli Lissick [email protected] (651) 276-6922 SOURCE Airiver Medical 21% more press release views with Request a Demo

11 Jun 2026

·www.biospace.com

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter Joel Hosein and Jashodeep Datta on the subject of IL1RAP as a Therapeutic Target in Pancreatic Cancer: The Case for Nadunolimab, on June 22, 2026. The KOL Call will be facilitated by Dr. Sara Nik, Vice President Equity Research at H.C. Wainwright, with the purpose of discussing IL1RAP as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC) and the emerging clinical role of nadunolimab (CAN04), Cantargia's anti-IL1RAP antibody. Despite decades of incremental progress, PDAC remains one of the most treatment-refractory malignancies. However, the PDAC treatment landscape is undergoing a meaningful inflection with RAS pathway targeting as a therapeutic priority. In parallel, the IL-1/IL1RAP axis has emerged as a critical mediator of the immunosuppressive and pro-tumorigenic PDAC microenvironment, representing a mechanistically distinct and potentially complementary approach. Against this evolving backdrop, we believe this KOL call presents a timely opportunity to explore the biology of IL1RAP in PDAC, discuss how nadunolimab may complement emerging RAS-directed strategies, and assess the potential of a planned Phase 1b/2a program to advance the treatment of this difficult disease. The KOLs Dr. Peter Joel Hosein is a medical oncologist at the University of Miami's Sylvester Comprehensive Cancer Center, specializing in gastrointestinal cancers with a particular focus on pancreatic cancer. He leads an active clinical and translational research program investigating novel therapeutic combinations for PDAC, including immune-targeting and stroma-modulating approaches. Dr. Jashodeep Datta is a surgical oncologist at the University of Miami's Sylvester Comprehensive Cancer Center, specializing in gastrointestinal and hepatobiliary malignancies. His research focuses on the tumor immune microenvironment in pancreatic cancer and the development of novel immunotherapeutic strategies targeting tumor-promoting inflammatory pathways. KOL Call details Title: IL1RAP as a Therapeutic Target in Pancreatic Cancer: The Case for Nadunolimab Date/Time: Monday, June 22 nd @ 11:00am ET (5:00pm CEST) Webcasting Link: KOLs : Dr. Peter Joel Hosein & Dr. Jashodeep Datta For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed. Cantargia is listed on Nasdaq Stockholm (ticker:CANTA). More information about Cantargia is available at . About nadunolimab (CAN04) Nadunolimab is an antibody that binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab has been investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316 , evaluated nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Intriguing efficacy was observed in a small group of non-squamous NSCLC patients post PD(L)-1 therapy. Attachments Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC SOURCE: Cantargia View the original press release on ACCESS Newswire

ImmunotherapyAcquisitionClinical Result

100 Deals associated with Albumin-Bound Paclitaxel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	China	CSPC Ouyi Pharmaceutical Co., Ltd.	10 Jun 2026
Neoplasms	Uruguay	Kexing Biopharm Co., Ltd.	31 Oct 2025
Metastatic Pancreatic Cancer	Peru	Zhejiang Haichang Bio-Tech Co., Ltd.	14 May 2025
Pancreatic Cancer	China	Bristol Myers Squibb Co.	05 Jan 2024
Pancreatic adenocarcinoma metastatic	United States	Teva Pharmaceuticals, Inc.	11 May 2023
Pancreatic carcinoma non-resectable	Japan	Taiho Pharmaceutical Co., Ltd.	18 Dec 2014
Stomach Cancer	Japan	Taiho Pharmaceutical Co., Ltd.	21 Feb 2013
Breast Cancer	China	Abraxis BioScience, Inc.	30 Jun 2008
Non-Small Cell Lung Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	European Union	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Iceland	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Norway	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Metastatic breast cancer	United States	Bristol Myers Squibb Co.	07 Jan 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Gastric Adenocarcinoma	Phase 3	China	CSPC Ouyi Pharmaceutical Co., Ltd.	01 Mar 2020
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Argentina	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Chile	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Czechia	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	France	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Hungary	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Italy	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Mexico	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Peru	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Poland	Hoffmann-La Roche, Inc.	10 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05827055 (PROGEM, ASCO2026)	Phase 1	Pancreatic Ductal Adenocarcinoma	6	Gemcitabine 1000 mg/m² IVNab-paclitaxel 125 mg/m² IV + Gemcitabine 1000 mg/m² IVNab-paclitaxel 125 mg/m² IV + Gemcitabine 1000 mg/m² IVNab-paclitaxel 125 mg/m² IV	bzrexwshvt(quxafuzmfa) = No AEs related to proglumide were reported ihqwexqhnp (gxrodpjdmv )	Positive	29 May 2026
ASCO2026	Not Applicable	Ovarian Epithelial Carcinoma First line	72	Dose-dense weekly paclitaxel (80 mg/m2 on days 1, 8, and 15) + Carboplatin (AUC 5)	kqluxfqvfx(itevxrekkv) = muusydyeet fhefhqhnia (hrreecuowm ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Ovarian Epithelial Carcinoma First line	72	Standard three-weekly paclitaxel (175 mg/m2) + Carboplatin (AUC 5)	kqluxfqvfx(itevxrekkv) = tpwmhrioxj fhefhqhnia (hrreecuowm ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Hemangiosarcoma Adjuvant	6	Nab-paclitaxel	ngjsjocnpd(bfqviuuodq) = vbceihmhqr yhexlatnay (cikerflolf, 6+ - 30+) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	101	tislelizumab+albumin-bound paclitaxel+ cisplatin	apivnznnxi(qomyevntln) = jldqvphswx ngfwrjvies (hltfzehkcn ) View more	Positive	29 May 2026
ASCO2026	Phase 2	Gallbladder Neoplasms First line	32	nab-paclitaxel+S-1+tislelizumab	ftachgjzls(gzebmlbgok) = bsezpbuypg ueglalyxhh (pgrppvksbj ) View more	Positive	29 May 2026
ChiCTR2500108269 (ASCO2026)	Phase 2	Locally Advanced Pancreatic Adenocarcinoma	45	Irinotecan liposome II + Adebelimab + gemcitabine + nab-paclitaxel	mmaywvzllp(rhjtheszpb) = cbgvlxfhyw rrhewoemer (pqudoqxxit )	Positive	29 May 2026
ASCO2026	Not Applicable	Locally Advanced Squamous Cell Carcinoma Neoadjuvant	113	Neoadjuvant albumin-bound paclitaxel plus cisplatin or carboplatin combined with a PD-1 inhibitor	iqoytdjlqh(mzrtxguend) = mqdklqvizv wyhzikkkaa (nsucxhhnxk ) View more	Positive	29 May 2026
NCT07259317 (TRIDENT, ASCO2026)	Phase 2	Metastatic Pancreatic Ductal Adenocarcinoma First line	60	Relacorilant + nab-paclitaxel + gemcitabine	dxufphinnb(zjbmrnxroy) = iwwpcjudmn glmqllcczs (rhkledrjxl, 24.95 - NR) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Breast Cancer PR Negative \| ER Negative \| HER2 Negative	2,259	BC treatments	pqakaqbwkq(kzyabimfxw) = sgsxahdxvk tinwmybfjf (tebwatkblv )	Negative	29 May 2026
ASCO2026	Not Applicable	Breast Cancer PR Negative \| ER Negative \| HER2 Negative	2,259	Other anticancer treatments	pqakaqbwkq(kzyabimfxw) = zrghxvylwy tinwmybfjf (tebwatkblv )	Negative	29 May 2026
NCT03377491 (PANOVA-3, ASCO2026)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	371	TTFields + gemcitabine/nab-paclitaxel	ykdymtkinn(dclhuqjiox) = xiatcbrgxc ibqgfhzcih (yybghymmil, 12.7 - 18.0) View more	Positive	29 May 2026
NCT03377491 (PANOVA-3, ASCO2026)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	371	gemcitabine/nab-paclitaxel	ykdymtkinn(dclhuqjiox) = tlrcywumsd ibqgfhzcih (yybghymmil, 11.5 - 15.4) View more	Positive	29 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Albumin-Bound Paclitaxel

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation